AriBio Co., Ltd.
Thursday, June 06, 2024
Company Presentation
![CNS/Neurological](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 1
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with office in San Diego, CA. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer’s disease. The lead asset, AR1001, is being developed as an investigational oral agent for treatment of Alzheimer’s disease in a global Phase 3 trial, AR1001-ADP3-US01 (POLARIS-AD, NCT05531526).
![AriBio Co., Ltd.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1825559-1-JPG.jpg)
Company Website:
https://www.aribio.com/
Lead Product in Development:
AR1001, a disease-modifying small-molecule agent being developed for Alzheimer's Disease
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Company HQ City
San Diego
Company HQ State
California
Company HQ Country
United States
CEO/Top Company Official
Jai Jun Choung
Development Phase of Primary Product
Phase III
Primary Speaker